The Diabetic Kidney Disease market has witnessed significant growth over the past few years owing to the rising prevalence of diabetes across the globe. Diabetic kidney disease, also known as diabetic nephropathy, is a condition in which the kidneys are damaged either due to type 1 or type 2 diabetes. It commonly develops in people who have had diabetes for a long period of time. The damage to the kidneys is mainly caused due to prolonged high blood sugar levels which can injure both the small blood vessels in the kidneys called the glomeruli and the tubules that help form urine. This may cause the kidneys to slowly lose their ability to filter waste from the blood. Some of the key symptoms include swelling in legs and ankles, high blood pressure, protein in urine, fatigue, breathing problems etc. The management of diabetic kidney disease involves controlling blood sugar levels, blood pressure and lifestyle modifications which is driving the growth of this market.

The Global Diabetic Kidney Disease Market is estimated to be valued at US$ 4.21 Bn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period of 2024 to 2031.

Key Takeaways

Key players operating in The Diabetic Kidney Disease Market are AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Bristol Myers Squibb, GSK, Novo Nordisk, Eli Lilly and Company, Merck & Co., Sanofi, AbbVie, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Lupin, Aurobindo Pharma, Takeda Pharmaceutical Company Limited, Biogen, Vertex Pharmaceuticals Incorporated. These players are focusing on developing new drugs and combination therapies to better manage the condition.

The growing demand for diabetic kidney disease treatment drugs can be attributed to the rising diabetes prevalence globally. As per IDF Diabetes Atlas 2019, around 463 million adults (20-79 years) are living with diabetes and by 2045 this will rise to 700 million. This rising diabetes burden is translating to an increasing diabetic kidney disease patient pool.

Technological advancements have enabled better understanding of disease pathology and progression. New biomarkers are being identified for early detection of kidney damage and staging of disease. Artificial intelligence and digital tools are being integrated into disease management approaches.

Market Trends

Personalized Medicine Approaches: There is a growing focus on developing personalized treatment regimens for diabetic kidney disease patients based on their individual disease characteristics, genetics, biomarkers etc. This enables targeted intervention pathways.

Combination Therapies: Companies are exploring combination drug therapies involving two or more therapeutic categories like SGLT2 inhibitors, GLP-1RAs, DPP-4 inhibitors etc. to achieve optimal glycemic and metabolic control for better kidney protection.

Market Opportunities

Late Stage Pipeline Drugs: Many companies have drugs in Phase III clinical trials for indications like slowing kidney function decline, reducing risk of end stage renal disease, cardiovascular outcomes etc. Approvals will drive market revenues.

Geographic Expansion: Major players are exploring opportunities in developing markets in Asia Pacific and Latin America driven by the rising disease burden in these regions. This will further boost the market growth.

Impact of COVID-19 on Diabetic Kidney Disease Market Growth:

The COVID-19 pandemic has significantly impacted the growth of the diabetic kidney disease market. The restrictions imposed during lockdowns hampered routine healthcare visits and hospital admissions. This led to underdiagnosis and treatment delays of diabetic kidney disease. The fear of contracting the virus in hospitals also discouraged patients from seeking medical care. Consequently, the market witnessed sluggish growth during the initial stages of the pandemic. However, as restrictions eased in 2021, demand gradually revived as patients resumed their regular check-ups and treatment plans. Telehealth also emerged as an alternative care delivery method during this period to ensure continuity of care. Going forward, the market is expected to pick up pace and register strong growth over the forecast period with resumption of normalcy. However, future waves of the pandemic still remain a threat that needs to be closely monitored. Post pandemic, adherence to treatment and lifestyle modifications will increase awareness levels. This will aid faster recovery and continued expansion of the market in the long run.

Regional Concentration in North America:

In terms of value, the diabetic kidney disease market is highly concentrated in North America. The region accounts for over 40% of the global market share led by developed healthcare infrastructure and systems in countries like the US and Canada. Heightened awareness regarding early diagnosis and prevention of disease progression also contributes to high market concentration. In addition, presence of leading pharmaceutical players engaged in new drug development further bolsters the regional market. Easy access to advanced treatment options, higher healthcare spending per capita, and favourable reimbursement policies foster early adoption of new treatment therapies. These factors are expected to help North America maintain its strong market dominance even during the forecast period.

Fastest Growing Region - Asia Pacific:

The Asia Pacific region is poised to be the fastest growing market for diabetic kidney disease over the forecast period. This is predominantly attributed to the growing diabetic population caused by increasing urbanization, sedentary lifestyles, and obesity in large countries like India and China. Rising prevalence of diabetes directly translates to higher risk of developing chronic kidney complications resulting in market expansion. Additionally, improving healthcare infrastructure, widespread health insurance penetration, and growing initiatives by governments to create awareness regarding diabetes management will propel the APAC market. As economies in the region develop further, investments in medical technology and drug innovation are also projected to accelerate growth prospects of diabetic kidney disease treatment in Asia Pacific.

Get more insights on Global Diabetic Kidney Disease Market